Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundació Sant Joan de Déu
• Collaborator: Servicio de Asesoría a la Investigación y Logística SL
• Treatments: Calcium heparin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• Women older than 18 years.

• Unique gestations

• Diagnosis of early placental intrauterine growth (according to Delphi classification):

<32 weeks at diagnosis + Doppler AU with absent / reverse flow or (estimated fetal weight <10 percentile + pulsed Doppler ultrasonography) or (estimated fetal weight

• Patient giving written informed consent to participate in the study.

Exclusion Criteria:

• Chromosopathies, genetic alterations or fetal malformations.

• Diagnostic treatment with low molecular weight heparins, oral anticoagulants or acetylsalicylic acid prior to inclusion.

• History of heparin-induced thrombocytopenia.

• Active hemorrhage or increased risk of bleeding due to changes in hemostasis.

• Severe hepatic or pancreatic function disorder.

• Organic lesions that may bleed (eg, active peptic ulcer, hemorrhagic stroke, aneurysms, or brain tumors).